Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 54% Improvement Relative Risk c19early.org/a Damayanti et al. Favipiravir for COVID-19 LATE Is late treatment with favipiravir beneficial for COVID-19? Retrospective 192 patients in Indonesia Improved recovery with favipiravir (p=0.029) Damayanti et al., Kesmas: National Public Health.., doi:10.21109/kesmas.v16i4.5433 Favors favipiravir Favors control
The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia
Damayanti et al., Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433
Damayanti et al., The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients in Bali, Indonesia, Kesmas: National Public Health Journal, doi:10.21109/kesmas.v16i4.5433
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 192 hospitalized patients in Indonesia, 96 patients treated with favipiravir, showing improved recovery with treatment. Only the abstract is currently available. This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of no recovery, 54.5% lower, RR 0.46, p = 0.03, treatment 96, control 96, adjusted per study, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Damayanti et al., 1 Nov 2021, retrospective, Indonesia, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit